A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat.

[1]  M. Madden,et al.  Extrahepatic Metabolism by CYP2E1 in PBPK Modeling of Lipophilic Volatile Organic Chemicals: Impacts on Metabolic Parameter Estimation and Prediction of Dose Metrics , 2007, Journal of toxicology and environmental health. Part A.

[2]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  Benoît Schilter,et al.  Tandem mass spectrometry analysis of N2-(trans-Isoestragol-3'-yl)-2'-deoxyguanosine as a strategy to study species differences in sulfotransferase conversion of the proximate carcinogen 1'-hydroxyestragole. , 2007, Chemical research in toxicology.

[4]  A. Sudalai,et al.  Enantioselective synthesis of (−)-cytoxazone and (+)-epi-cytoxazone, novel cytokine modulators via Sharpless asymmetric epoxidation and l-proline catalyzed Mannich reaction , 2006 .

[5]  Andreas Reichel,et al.  Development and Application of Physiologically Based Pharmacokinetic‐Modeling Tools to Support Drug Discovery , 2005, Chemistry & biodiversity.

[6]  R. Andersen,et al.  Metabolism of thymol and trans-anethole in larvae of Spodoptera litura and Trichoplusia ni (Lepidoptera: Noctuidae). , 2004, Journal of agricultural and food chemistry.

[7]  L. Iyer,et al.  Glucuronidation of 1'-hydroxyestragole (1'-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  B. Wong,et al.  Complexities of glucuronidation affecting in vitro in vivo extrapolation. , 2002, Current drug metabolism.

[9]  Ginette Truchon,et al.  Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. , 2002, Toxicology letters.

[10]  J I Goodman,et al.  Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  P. van Bladeren,et al.  Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling. , 2001, Chemico-biological interactions.

[12]  A. Schuster,et al.  First-pass metabolism of 1,3-butadiene in once-through perfused livers of rats and mice. , 2001, Chemico-biological interactions.

[13]  T. Guenthner,et al.  Investigation of the role of the 2',3'-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. , 2001, Toxicology.

[14]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  M. Andersen,et al.  Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  P. van Bladeren,et al.  A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. , 1997, Toxicology and applied pharmacology.

[17]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[18]  T. Guenthner,et al.  Covalent binding to DNA in vitro of 2',3'-oxides derived from allylbenzene analogs. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[19]  M. Gargas,et al.  In Vivoandin VitroStudies of Perchloroethylene Metabolism for Physiologically Based Pharmacokinetic Modeling in Rats, Mice, and Humans , 1996 .

[20]  N. Lebel,et al.  Synthesis of (-)-Monoterpenylmagnolol and Magnolol , 1995 .

[21]  J. A. Bond,et al.  In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. , 1994, Carcinogenesis.

[22]  C. Evelo,et al.  Cancer mortality in African and Caribbean migrants to England and Wales. , 1992, British Journal of Cancer.

[23]  T. Guenthner,et al.  Hydrolysis of the 2',3'-allylic epoxides of allylbenzene, estragole, eugenol, and safrole by both microsomal and cytosolic epoxide hydrolases. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Caldwell,et al.  Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1'-hydroxyestragole. , 1987, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[25]  E C Miller,et al.  Structure-activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J x C3H/HeJ F1 mice. , 1987, Cancer research.

[26]  E C Miller,et al.  Further characterization of the DNA adducts formed by electrophilic esters of the hepatocarcinogens 1'-hydroxysafrole and 1'-hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of guanine residues. , 1985, Cancer research.

[27]  K Randerath,et al.  32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. , 1984, Carcinogenesis.

[28]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[29]  E C Miller,et al.  Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. , 1983, Cancer research.

[30]  G. Mulder,et al.  Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes. The role of saturation of phenolsulfotransferase. , 1981, Biochemical pharmacology.

[31]  E C Miller,et al.  Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1'-hydroxyestragole in the mouse and mutagenicity of 1'-acetoxyestragole in bacteria. , 1976, Journal of the National Cancer Institute.

[32]  E Solheim,et al.  Metabolism of alkenebenzene derivatives in the rat. I. p-Methoxyallylbenzene (Estragole) and p-methoxypropenylbenzene (Anethole). , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  W. Beierschmitt,et al.  Age-related changes in renal metabolism of acetaminophen in male Fischer 344 rats , 2006, AGE.

[34]  M L Shuler,et al.  Use of In Vitro Data for Construction of a Physiologically Based Pharmacokinetic Model for Naphthalene in Rats and Mice To Probe Species Differences , 1999, Biotechnology progress.

[35]  J. DeJongh,et al.  A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans , 1997, Archives of Toxicology.

[36]  E C Miller,et al.  Structures of the DNA adducts formed in mouse liver after administration of the proximate hepatocarcinogen 1'-hydroxyestragole. , 1981, Cancer research.